Situated at Tanzhou Town, Zhongshan City and neighboring the hometown of great politician Sun Yat-sen,Zhuhai United Laboratories（Zhongshan） Co. is a production site with pharmaceutical preparation as the major product. The plant was completed and put into production in 1996, and in 1997 it becameone of the earliest pharmaceutical preparation production enterprises that have many of their dosage forms recognized by national GMP certification.
　　TUL zhongshan has over 1,000 employees, of whomtechnicians with bachelor degree or above takes up over 25%. Being engaged with the R&D, production and marketing of medical products, it generates an output value of over RMB 3 billionevery year. The plant occupies an area of over 80,000 m2 with a floor area of 140000 m2 and is established with a R&D center and over 10 preparation workshops. The dosage forms produced comprise capsules, biological agents, granules, oral solution, powder injection, eye drops, oniments, etc. It can currently produce 24 million tubes of recombinant human insulin biological agent, 1.8 billion capsules, 1 billion tablets and 27.5 million tubes of lyophilized powder for injection, which are sold to regions both in and outside China.
　　The company's leading products includeantibiotics and recombinant human insulin. Besides, it also produces antipyretic-analgesic drugs, antitussive drugs, antiviral agents, dermatosis drugs, anti-hepatitis drugs, ophthalmic remedies and high-end healthcare food. The knock-out products "Amoxy"(amoxicillin preparations) and tazocin has become the first-line drugs used in domestic third-level grade-A hospitals. Amoxy, Strong Amoxy, Ampicillin, Tazocin, USLIN (recombinant human insulin series preparations), Liang Jing Jing (Sodium Hyaluronate Eye Drops), A Di Xian (Adefovir Dipivoxil Capsules) and other series products are recognized as hi-tech products of Guangdong Province.
　　As the production and research center of Zhuhai United Laboratories Co., Ltd., the company successively won the titles of the national-level "Post-Doctoral Research Center", the "High and New Technology Enterprise of Guangdong Province", the "R&D Center of Anti-infective Drug Engineering Technology of Guangdong Province", etc. It always persists in technology innovation and increases its capital input to new drug R&D gradually. Through self-dependent innovation and external horizontal collaboration, the company has developed a number of new products involving many cutting-edge therapeutic fields at home and abroad such as anti-infectives, antivirals, antineoplastic, drugs for diabetes, respiratory system, nervous system, heart and cerebral vessel diseases, etc.
　　The company always practices a whole-process production quality management and control system with high standards and strict requirements, and has now become one of the first-echelon pharmaceutical enterprises in China through over 20 years of development.